Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Brain Neoplasms 3Urinary Bladder Neoplasms 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Osteosarcoma 1Osteonecrosis 1Osteomyelitis 1Lung Carcinoma Metastatic in the Brain 1Kidney Neoplasms 1Glioblastoma 1Cranial Nerve Diseases 1Chondrosarcoma 1Central Nervous System Neoplasms 1Bone Neoplasms 1

Interventions

aldesleukin 22Sunitinib 21Bevacizumab 16Interleukin-2 14Everolimus 14Interferon-alpha 13Gemcitabine 13Cyclophosphamide 13fludarabine phosphate 11Peripheral Blood Stem Cell Transplantation 9Sorafenib 8Filgrastim 8Axitinib 8Nivolumab 7pembrolizumab 6Ipilimumab 6Doxorubicin 6Carboplatin 6sargramostim 5cabozantinib 5Capecitabine 5Thalidomide 4Tacrolimus 4Radiotherapy 4Radiosurgery 4Neoadjuvant Therapy 4Mycophenolic Acid 4Magnetic Resonance Spectroscopy 4Erlotinib Hydrochloride 4Chemotherapy, Adjuvant 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Kidney Neoplasms × Ferrosoferric Oxide × Clear all
NCT02141490 2019-09-06

Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
43 enrolled 12 charts
Genitourinary

Urinary Bladder Neoplasms, Kidney Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡